Minerva Neurosciences Reports Director/Officer Changes & Compensation
Ticker: NERV · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1598646
Sentiment: neutral
Topics: management-change, compensation, corporate-governance
Related Tickers: NERV
TL;DR
Minerva Neurosciences (NERV) filed an 8-K detailing director/officer changes and compensation updates.
AI Summary
Minerva Neurosciences, Inc. filed an 8-K on November 19, 2025, reporting events as of November 14, 2025. The filing indicates a departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with updates on compensatory arrangements for these officers. It also includes a Regulation FD disclosure and financial statements with exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if unexpected, can indicate internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- Minerva Neurosciences, Inc. (company) — Registrant
- November 14, 2025 (date) — Earliest event reported
- November 19, 2025 (date) — Date of report
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates a departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any updates to the compensation of officers?
Yes, the filing mentions compensatory arrangements of certain officers.
What is the primary purpose of this 8-K filing?
The filing serves as a current report detailing significant events such as director/officer changes, elections, appointments, and related compensation, along with a Regulation FD disclosure and financial exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on November 14, 2025.
What is Minerva Neurosciences, Inc.'s principal executive office address?
The principal executive offices are located at 1500 District Avenue, Burlington, MA 01803.
Filing Stats: 1,584 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2025-11-19 08:40:06
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share NERV The Nasdaq
- $40,000 — nsation Plan, Dr. Kaul is entitled to a $40,000 annual cash retainer for his service on
- $450 — y 25 to 30 hours per month at a rate of $450 per hour during a six-month initial ter
Filing Documents
- d48648d8k.htm (8-K) — 35KB
- d48648dex101.htm (EX-10.1) — 48KB
- d48648dex991.htm (EX-99.1) — 12KB
- g48648g1118111127861.jpg (GRAPHIC) — 4KB
- 0001193125-25-287048.txt ( ) — 233KB
- nerv-20251114.xsd (EX-101.SCH) — 3KB
- nerv-20251114_lab.xml (EX-101.LAB) — 17KB
- nerv-20251114_pre.xml (EX-101.PRE) — 11KB
- d48648d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Consulting Agreement dated as of November 14, 2025, by and between the Registrant and Inderjit Kaul 99.1 Press release dated November 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Indicates management contract or compensatory plan or arrangement. 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 19, 2025 MINERVA NEUROSCIENCES, INC. /s/ Remy Luthringer Remy Luthringer Chief Executive Officer 4